Despite no public indication of Cliff Asness identifying Neurocrine Biosciences (NASDAQ: NBIX) as a significant pick, analysts have shown confidence in the company's potential for growth. Asness, known for his strategic investments, typically reveals his stock preferences through regulatory filings like 13F reports, though these documents are not available in real-time.
Analyst consensus suggests a "Moderate Buy" rating on Neurocrine Biosciences, with 24 analysts providing an average one-year target price of $163.91, as reported by ETF Daily News. The company’s stock price targets range between $114.00 and $192.00 per share, indicating a potential rise from its current valuation, according to Market Inference.
Neurocrine's future appears optimistic due to several ongoing Phase II clinical trials, with results anticipated in 2024, as highlighted by Morning Strong. These developments could strengthen the company's growth prospects, though investors are advised to align such insights with their individual financial objectives.